Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

CANC

Tema Oncology ETF (CANC)

Rating:61Neutral
Price Target:$44.00â–²(7.16% Upside)

CANC, the Tema Oncology ETF, has a solid but not top-tier rating, reflecting a mix of strong established pharma leaders and riskier biotech names. High-quality holdings like Merck, Novartis, Eli Lilly, and Exelixis, all supported by robust financial performance and promising drug pipelines, are key positives that lift the fund’s quality. However, weaker positions such as Cogent Biosciences and some loss-making or overvalued biotechs introduce higher risk, and the fund’s focus on oncology means it is concentrated in a single, often volatile sector.

Positive Factors
Strong Year-to-Date PerformanceThe ETF has delivered strong gains so far this year, showing solid momentum in its oncology-focused strategy.
Leading Healthcare HoldingsSeveral top positions, including large, well-known drug makers and successful biotech names, have shown strong performance and help support the fund’s returns.
Focused Exposure to OncologyThe fund’s heavy focus on health care and oncology companies gives investors targeted access to a specialized area of the market that has been performing well overall.
Negative Factors
High Expense RatioThe ETF charges relatively high annual fees, which can eat into long-term returns compared with lower-cost funds.
Sector Concentration RiskWith almost all assets in health care, the fund is heavily exposed to risks specific to drug development, regulation, and reimbursement changes.
Single-Country and Stock-Specific RisksThe strong tilt toward U.S. companies and the presence of at least one weakly performing top holding increase vulnerability to both domestic market swings and individual company setbacks.

CANC vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%SPY+14.55%CANC+21.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
212.25M
Region
Global
Expense Ratio
0.75%
Beta
0.73
Issuer
Tema
Inception Date
Aug 15, 2023
Dividend Yield
0.05%
Asset Class
Equity
Index Tracked
No Underlying Index

CANC Summary

The Tema Oncology ETF (ticker CANC) is a fund that focuses on companies involved in cancer research and treatment, mainly in the U.S. health care sector. It does not track a traditional index, but instead follows the theme of oncology, investing in drug makers and biotech firms working on new cancer therapies. Well-known holdings include Merck & Company and Eli Lilly, along with smaller, specialized biotech companies. Someone might invest in this ETF for potential long-term growth and to support innovation in cancer care. A key risk is that biotech and pharma stocks can be very volatile, so the fund’s value can go up and down sharply.

How much will it cost me?

This ETF has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed and focuses on a specialized niche in oncology rather than tracking a broad, low-cost index.

What would affect this ETF?

This oncology-focused ETF could benefit if major drug makers like Eli Lilly, Merck, Novartis, and AbbVie successfully launch new cancer treatments, if global health care spending grows, and if supportive regulations speed up approvals for innovative therapies. On the negative side, setbacks in clinical trials, stricter drug pricing rules, or a weaker global economy that pressures health care budgets could hurt the fund, especially given its heavy concentration in a single, volatile niche of the health care sector.

CANC Top 10 Holdings

This oncology-focused ETF is heavily tilted toward health care, with big drugmakers like Merck, Eli Lilly, Novartis, and AbbVie providing the steady backbone of performance as their cancer franchises keep humming along. Genmab and Halozyme are the fund’s real bright spots, rising on strong results and upbeat outlooks. On the flip side, Cogent Biosciences has been lagging, acting like a small anchor on an otherwise upbeat portfolio. With a global mix of U.S. and European names, the fund is concentrated in oncology innovators rather than any single country.

CANC top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
GMABGMABGenmab5.83%$12.26M$30.47B69.87%76Outperform
RVMDRVMDRevolution Medicines5.44%$11.44M$37.27B167.61%52Neutral
LLYLLYEli Lilly & Co5.53%$11.63M$1.36T41.12%72Outperform
MRKMRKMerck & Company4.98%$10.47M$364.26B59.00%80Outperform
COGTCOGTCogent Biosciences4.37%$9.19M$4.97B-15.58%37Underperform
ONCONCBeOne Medicines4.31%$9.07M$46.69B13.08%61Neutral
CH:NOVNCH:NOVNNovartis AG4.20%$8.83MCHF 245.40B26.78%80Outperform
ABBVABBVAbbVie3.85%$8.10M$521.50B27.01%66Neutral
EXELEXELExelixis3.77%$7.93M$16.84B62.93%78Outperform
BBIOBBIOBridgeBio Pharma3.18%$6.69M$15.25B20.35%59Neutral

CANC Technical Analysis

Technical Analysis SentimentNegative
Last Price41.06

Price Trends

50DMA41.56Negative
100DMA41.89Negative
200DMA39.54Positive

Market Momentum

MACD0.12Positive
RSI46.36Neutral
STOCH31.07Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CANC, the sentiment is Negative. The current price of 41.06 is below the 20-day moving average (MA) of 41.79, below the 50-day MA of 41.56, and above the 200-day MA of 39.54, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 46.36 is Neutral, neither overbought nor oversold. The STOCH value of 31.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANC.

CANC Peer Comparison

Comparison Results

CANC against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
CANCCANC$41.06$44.00(7.16% Upside)$212.25M0.75%61Neutral
AVREAVRE$47.09$52.06(10.55% Upside)$895.31M0.17%66Neutral
BLOKBLOK$49.96$82.00(64.13% Upside)$827.94M0.70%56Neutral
CSRECSRE$28.93$32.23(11.41% Upside)$720.68M0.70%68Neutral
VOLTVOLT$33.28$43.70(31.31% Upside)$701.68M0.75%70Neutral
ARKXARKX$29.22$44.19(51.22% Upside)$657.99M0.75%59Neutral

Performance Comparison

0%20%40%CANCAVREBLOKCSREVOLTARKXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CANC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CANCTema Oncology ETF41.067.5022.33%
AVREAvantis Real Estate ETF47.094.6110.84%
BLOKAmplify Transformational Data Sharing Etf49.96-7.74-13.42%
CSRECohen & Steers Real Estate Active ETF28.933.7614.92%
VOLTTema Electrification ETF33.284.2214.52%
ARKXARK Space Exploration & Innovation ETF29.222.117.78%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.